Severe cutaneous adverse reactions (SCAR) syndromes  by Marotti, Miriam
AT THE BEDSIDE
Rev Assoc Med Bras 2012; 58(3):276-278
Pharmaceutical Medicine
Severe cutaneous adverse reactions (SCAR) syndromes
MIRIAM MAROTTI
Global Safety Physician, Patient Safety Astrazeneca, Cheshire, UK
Correspondence to: AstraZeneca, Research & Development, Patient Safety, Parklands, Alderley Park, Macclesﬁeld, Cheshire, UK – SK10 4TG  – miriam.marotti@astrazeneca.com 
©2012 Elsevier Editora Ltda. 
Idiosyncratic drug reactions are unpredictable reac-
tions that can cause significant morbidity and mortality. 
The causal mechanisms continue to be unclear and be-
cause of the lack of consensus regarding the definition of 
these syndromes, reports, and therefore epidemiological 
data, are often unreliable.
Severe idiosyncratic drug reactions are often char-
acterized by fever and internal organ involvement. They 
also frequently involve the skin, which amount to less 
than 5% of the reported drug reactions in hospitalized 
patients, and probably more than 90% of these are related 
to an unpredicted effect mediated by a drug that activates 
the immune response. The clinical presentation is highly 
variable, from the most common transient and benign 
erythema that occurs six to nine days after the introduc-
tion of a new drug in 1% to 3% of users, to the most severe 
forms that fortunately affect less than 1/10,000 users1. 
 In order to establish a common criteria to re-
fer to these entities, the RegiSCAR-group proposed the 
denomination of severe cutaneous adverse reactions 
(SCAR) for the very rare disorders that are severe and 
often associated with significant morbidity and mortal-
ity, non-predictable or idiosyncratic, and most frequently 
caused by drugs2.  
ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS (AGEP)
Acute generalized exanthematous pustulosis (AGEP) was 
described as an entity in the 1980’s as an extensive pustu-
lar eruption similar to pustular psoriasis, usually taking 
place as a drug reaction in patients without a history of 
psoriasis; the mortality rate has been consistently report-
ed in the medical literature as 5%3. 
The diagnosis criteria include acute pustular eruption, 
fever above 38°C, neutrophilia with or without a mild eo-
sinophilia, subcorneal or intraepidermal pustules on skin 
biopsy, and spontaneous resolution in less than 15 days4.
STEVENS-JOHNSON SYNDROME (SJS) AND TOXIC  
EPIDERMAL NECROLYSIS (TEN)
Stevens-Johnson syndrome (SJS) is characterized by acute 
onset and rapid progression of painful skin and mucous 
membranes lesions. The skin lesions are widespread and 
predominate on the trunk, with a tendency to become 
confluent, leading to a restricted detachment of epidermis 
on less than 10% of the body surface area.
Toxic epidermal necrolysis (TEN), described in 1956 
by Lyell (Lyell’s syndrome), is characterized by the same 
lesions as SJS but with the detachment of large epidermal 
sheets on more than 30% of the body surface area.
Based on the results of a large case control study, the 
RegSCAR group suggested that SJS and TEN can be con-
sidered as severity variants of a single disease5. 
A severity-of-illness score that estimates the risk of 
death in toxic epidermal necrolysis6 has been developed 
and validated. The authors identified seven independent 
risk factors for predicting an outcome of death in TEN 
cases: 
1. Age > 40 years 
2. Heart rate > 120 beats per minute 
3. Cancer or hematologic malignancy 
4. Involved body surface area > 10% 
5. Blood urea nitrogen level > 10 mmol/L (28 mg/dL) 
6. Serum bicarbonate level < 20 mmol/L (20 mEq/L) 
7. Blood glucose level 14 mmol/L (252 mg/dL)
Mortality rates based on the number of positive crite-
ria are as follows: 
t UPGBDUPS
t GBDUPST
t GBDUPST
t GBDUPST
t PSNPSFGBDUPST
The opinion regarding the usefulness of specific treat-
ments varies, since some results show no benefit from us-
ing intravenous immunoglobulin and a strong (but not 
significant) potential reduction of mortality with the use 
of corticosteroids7. 
DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
(DRESS SYNDROME)  
Drug rash with eosinophilia and systemic symptoms 
(DRESS syndrome) was defined by the triad of skin erup-
tion, haematological involvement, and internal organ 
involvement according to Bocquet’s diagnosis criteria 
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in 19968, in order to differentiate it from drug-induced 
pseudo lymphoma, and comprises the following criteria:
 1. Cutaneous drug eruption
 2. Hematologic abnormalities: eosinophilia or  
  presence of atypical lymphocytes
 3. Systemic involvement:
Adenopathies ≥ 2 cm in diameter
or hepatitis (liver tronsaminases values ≥ 2 N)
or interstitial nephritis
or interstitial pneumonitis
or carditis
It has been estimated to occur in about 1 in 10,000 ex-
posures to drugs such as antiepileptics and sulfonamides. 
It typically begins two to six weeks after first drug use, 
later than most other skin reactions. Visceral involve-
ment differentiates DRESS syndrome from common ex-
anthematous eruptions8.
Prominent eosinophilia is common, and a character-
istic feature of this reaction is the appearance of atypi-
cal lymphocytosis in the circulation. Rash and hepatitis 
may persist for several weeks after drug withdrawal, and 
some of the manifestations may be life-threatening, with 
a mortality rate of about 10%.
The differential diagnosis includes acute viral infec-
tions, idiopathic hypereosinophilic syndrome, and lym-
phoma.  Special attention should be paid to human her-
pesvirus-6 (HHV6), since several publications suggested 
a possible interaction between DRESS and reactivation 
of HHV6.
A peculiar feature of this syndrome is its long-lasting 
clinical course despite withdrawal of the causative drug. 
There may also be persistent intolerance to other chemi-
cally distinct drugs, leading to flare-up reactions months 
after the initiating drug therapy is stopped. Recently, it 
has been shown that HHV6 DNA can be found in many 
patients with this syndrome during the third or fourth 
week of the disease (but not before), followed by an in-
crease in antibodies to HHV69. Other reports document 
reactivation of cytomegalovirus infection.  The justifica-
tion is that a drug-induced massive immune stimulation 
somehow leads to a loss of control of these herpes virus-
es, which subsequently replicate and possibly contribute 
to the chronic course and persistent drug intolerance 
characteristic of this disease10. 
The aromatic antiepileptic agents (phenobarbital, car-
bamazepine, phenytoïn), minocycline, and allopurinol 
are the most frequent causes.  Sulfonamides, gold salts, 
and dapsone may also induce this syndrome11.  
Experts agree that the decision of whether an organ 
is involved by DRESS should rely on two criteria: clinical 
relevance and absence of other alternative causes. As an 
example, the liver would be considered involved if alanine 
aminotransferase levels were at least twice the upper limit 
of normal values in the absence of another disease. 
Japanese authors classify a subset of DRESS as drug in-
duced hypersensitivity syndrome (DIHS) if containing the 
following features: maculo-papular rash; prolonged clinical 
symptoms two weeks after discontinuation of the causative 
drug; fever higher than 38oC; liver abnormalities (alanine 
aminotransferase [ALT] >  100 U/L); leukocyte abnor-
malities, including leukocytosis (> 11 x 109 leukocytes/L), 
atypical lymphocytosis (>  5% lymphocytes), or eosino-
philia (> 1.5 x 109 eosinophils/L); lymphadenopathies; and 
HHV6 reactivation. Diagnosis of definite or typical DIHS 
requires the presence of the seven criteria and might be a 
more severe expression of DRESS11.
CLINICAL ASPECTS AND DIAGNOSIS
The diagnosis of severe cutaneous drug reactions (SCAR) 
requires the identification of a skin eruption with high fe-
ver and severe constitutional symptoms that might have 
been caused by a medication and not by another cause. 
The differential diagnosis includes other cutaneous drug 
reactions, acute viral infections (e.g., Epstein-Barr virus, 
hepatitis virus, influenza virus, cytomegalovirus, and 
human immunodeficiency virus), lymphoma, pseudo-
lymphoma, idiopathic hypereosinophilic syndrome, and 
angio-immunoblastic lymphadenopathy.  In addition, 
while some medications are “usual suspects” for all types 
(e.g. anticonvulsants), others are more specific of a given 
pattern (pristinamycine, hydroxychloroquine, and diltia-
zem for AGEP; minocycline for DRESS; anti-infectious 
sulfonamides and allopurinol for epidermal necrolysis). 
The identification of organ involvement, which differs 
according to the type of reaction, is another important 
point for the diagnostic confirmation of SCAR entities. 
The “phenotypic” diversity of the final expression 
drug reactions can be explained by the engagement of a 
variety of cytokines and inflammatory cells, and by regu-
latory mechanisms.  For example, memory cytotoxic T-
cells are key effectors in extensive blisters of epidermal 
necrolysis.
With this in mind, prognosis can be determined, and 
recovery after drug withdrawal is usual, but symptoms may 
persist for several weeks. When internal organ involve-
ment exists, treatment with systemic corticosteroids is of-
ten proposed even though the efficacy of corticosteroids 
has not been proved to be useful for all entities described.
CONCLUSION
The denomination of severe cutaneous adverse reactions 
(SCAR) defines very rare disorders that are severe and of-
ten associated with significant morbidity; these disorders 
are idiosyncratic and most frequently caused by drugs, 
and mortality ranges from 5% to 40%.
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For a better understanding of these clinical entities 
a consensus on the definition will help reliable report-
ing, and therefore superior epidemiological data will be 
available.
Recognition is of fundamental importance since re-
covery after drug withdrawal is usual, but symptoms may 
persist for several weeks. When internal organ involve-
ment exists, treatment with systemic corticosteroids is 
often proposed.
It is important to remember that all these entities 
are associated with drug use, and that the accuracy of 
adverse reaction reporting, which in turn relies on the 
recognition of these entities and their diagnoses in the 
clinical setting, is of paramount importance for the rec-
ognition of potential drug-related associations and helps 
to define the safety profile of drugs.
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